Table 3.
Cell lines from ovarian clear cell carcinoma
| Cell line | Age | Materials | Chromosome number | DT (hour) | Transplantability | Immunotaining | Characteristics |
|---|---|---|---|---|---|---|---|
| HUOCA-II (1987) | 51 | Ovary | 46 (mode) | 24, 28 | Yes | - | Tumor angiogenesis factor |
| RMG-I (1988) | 34 | Ascites | 47 (mode) | 60 | Yes | BFP, ferritin, PLAP | - |
| OCC1 (1990) | 47 | Ascites | 70–77 | 36, 38 | Yes | - | Production of CA125 |
| RMG-II (1991) | 53 | Ascites | hypertetraploid | 58 | No | CA125, TPA, MA602-1, MA602-6 | Production of CA125, TPA, MA602-1, MA602-6 |
| OVISE (1995) | 40 | Metastatic tumor | 62 (59–65) | 60 | Yes | CA125, CA19-9, EGFR, ER(−), PgR(−) | Production of CA19-9, CA125, TPA |
| OVTOKO (1995) | 78 | Metastatic tumor | 78 (76–83) | 70 | Yes | EGFR, ER(−), PgR(−) | - |
| JHOC-5 (1999) | 47 | Ovary | 74–85 | 52 | No | - | CA125 |
| JHOC-6 (1999) | 43 | Recurrent tumor | 46–49 | 70 | Yes | - | CA125 |
| SMOV-2 (1999) | 46 | Tumor | 85–92 | 48.2 | Yes | - | p53 mutation (−) |
| TAYA (2002) | 43 | Ascites | 69–74 | 50 | No | - | p53 Exon5 point mutation, PTEN mutation (−) |
| RMG-V (2005) | 52 | ascites | 83 (77–85) | 15.5 | No | - | - |
| TU-OC-1 (2013) | 65 | Ovary | 64–69 | 38.4 | Yes | - | PIK3CA mutation (+) |
| HCH-1 | 67 | Ovary | 39–44 | 48.7, 66.4 | Yes | CA125, CA19-9, ER(−), PgR(−) | production of CA19-9, CA125, TPA |
DT doubling time (hour)